• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

ARVO 2024: Study finds association between lower vision-specific quality of life and cortical/cerebral visual impairment in children

News
Article

Investigators recruited children with CVI and normal controls who were between the ages of 12 months and 12 years. They concluded that children with CVI have markedly lower VS-QOL compared to typically developing children.

Child working with glasses on table Image Credit: AdobeStock/irena_geo

Image Credit: AdobeStock/irena_geo

Cortical/cerebral visual impairment (CVI), a visual processing disorder and the leading cause of visual impairment among children in developed countries is associated with markedly lower vision-specific quality of life (VS-QOL) in affected children compared to typically developing children, according to Michelle Lin, MD, from the University of California Riverside, Riverside, CA. She discussed her findings at the Association for Research in Vision and Ophthalmology annual meeting in Seattle.

She and colleagues Mark Borchert, MD, and Melinda Chang, MD, both from Children's Hospital Los Angeles, and the University of Southern California, Los Angeles, undertook a prospective cohort study to characterize the VS-QOL in children with CVI and assess the effect of clinical factors on these measures.

The investigators recruited children with CVI and normal controls who were between the ages of 12 months and 12 years. The children with CVI underwent a complete pediatric neuro-ophthalmologic examination.

During the assessment, the children’s caregivers completed the Children’s Visual Function Questionnaire (CVFQ). The scores achieved by the questionnaire were compared between the patients with CVI and the controls. The investigators sought associations between the visual acuity, strabismus, nystagmus, and optic atrophy and the CVFQ scores.

Assessment findings

A total of 43 children with CVI and 21 typically developing controls were included in this study (median respective ages, 5 and 3 years; p=0.21).

Lin reported, “All children with CVI had a developmental age less than 7 years, and all controls had a chronologic age less than 7 years (the upper age limit at which the CVFQ is validated). Children with CVI demonstrated significantly lower CVFQ scores than controls.”

Specifically, the respective total CVFQ scores for the affected children and controls were0.58±0.13 and 0.95±0.06; competence subscale scores, 0.42±0.26 and 0.96±0.08; personality subscale scores, 0.72±0.13 and 0.91±0.13; and family impact subscale score, 0.58±0.18 and 0.94±0.10) (p<0.0001 for all comparisons).

She also reported that the visual acuity, optic atrophy, and nystagmus did not significantly affect the CVFQ scores, but a history of strabismus was associated with worse CVFQ family impact subscale scores (0.52±0.16 vs. 0.69±0.19, p=0.03).

The investigators concluded that children with CVI have markedly lower VS-QOL compared to typically developing children. While the visual acuity was not significantly correlated with the VS-QOL, a history of strabismus was associated with worse VS-QOL, ie, specifically, greater impact on the family.

She stated, “Our findings highlight the profound impact of a CVI diagnosis on both the affected child and family members, and illustrate the importance of factors other than visual acuity on the VS-QOL in CVI.”

Reference:
  1. Lin M, Bochert M, Chang M. Vision-Specific Quality of Life in Children with Cortical/Cerebral Visual Impairment (CVI). Paper presented at: Association for Research in Vision and Ophthalmology annual meeting; May 5-9, 2024; Seattle, WA. Abstract number: 2147
Related Videos
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Shelley Cutler, OD, FAAO, outlines her key takeaways from this year's IKA symposium
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Emily Chew, MD, outlines her lecture that landed her the Proctor Award at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.